(IN BRIEF) Sanofi's experimental CD40L antibody, frexalimab, demonstrates encouraging results in a 48-week phase 2 study for relapsing multiple sclerosis…
(IN BRIEF) Roche, a leading healthcare company, has announced that its Elecsys Neurofilament Light Chain (NfL) test for Multiple Sclerosis…
(IN BRIEF) Alexion, a subsidiary of AstraZeneca Rare Disease, is set to present new data at the 9th Joint Meeting…
(IN BRIEF) Roche has announced positive late-breaking data from the Phase III OCARINA II study, which demonstrates the effectiveness of…
(IN BRIEF) Merck has presented new data on evobrutinib, an investigational BTK inhibitor, at the 9th Joint ECTRIMS-ACTRIMS congress. The…
(IN BRIEF) Merck, a prominent science and technology company, has revealed new findings from the MAVENCLAD® (cladribine tablets) MAGNIFY-MS study…
(IN BRIEF) H.U. Group Holdings Inc. and Fujirebio have announced the launch of Lumipulse G NfL CSF and Lumipulse G…
(PRESS RELEASE) ENSCHEDE, Netherlands, 28-Feb-2022 — /EuropaWire/ — University of Twente, a Enschede, NL based public technical university, has announced…
Further strengthens core R&D areas of autoimmune and allergic diseases Provides full control of brain-penetrant BTK inhibitor SAR442168 in multiple…
GENEVA, 16-May-2018 — /EuropaWire/ — Multiple sclerosis, which affects 1 in 1,000 people, is frequently characterised by relapses associated with variable…
Participation in private placement as a cornerstone investor EBRD participates in US$ 51m equivalent private placement of Mabion Mabion is…
Medicine to be voluntarily withdrawn from the market by the company LONDON, 06-Mar-2018 — /EuropaWire/ — The European Medicines Agency (EMA)…
Novartis and Pear Therapeutics to collaborate on prescription software applications aimed to treat patients with schizophrenia and multiple sclerosis Collaboration…
MUNICH, 09-Jan-2018 — /EuropaWire/ — Multiple Sclerosis (MS) is a chronic inflammatory disease of the central nervous system, in…
Preliminary research indicates most MS carers are between the ages of 18-34, the prime of their lives Largest global MS…
Subgroup analysis shows >80% reduction in the risk of disability progression with Cladribine Tablets vs placebo DARMSTADT, 02-May-2017 — /EuropaWire/…
A large global new partnership called 'MultipleMS', coordinated by Karolinska Institute in Sweden, has been awarded 15 million euro from…
On 9 September, Proximus received the MS@Work 2015 Award. The Award was presented by the National Belgian Multiple Sclerosis League…
Novartis strengthens multiple sclerosis focus with the addition of Ofatumumab to leading MS portfolio which includes Gilenya and investigational treatments…
The new RebiSmart® injection device offers many new updates including wireless transmission of injection times and doses MSdialog™software is designed to…
16-8-2013 — /EuropaWire/ — Immunologists at LMU have come up with a new technique that can be used both to fight…
Princeton, New Jersey, 29-7-2013 — /EuropaWire/ — Sandoz announced today that the US Federal Circuit Court of Appeals has invalidated several patents…
Cordoba, Spain, 12-6-2013 — /europawire.eu/ — VivaCell Biotechnology España S.L., Cordoba, Spain today announced that it has entered into joint Research Collaboration…